EnWave has granted Merck an exclusive research license to use its technology and licensed patents for the duration of the evaluation, besides providing an option to obtain an exclusive commercial worldwide license to EnWave’s portfolio.
As per the deal, Merck will conduct a field test to determine the feasibility of the Radiant Energy Vacuum (REV) Technology using EnWave’s new multi-vial pilot-scale equipment.
EnWave’s dehydration technology portfolio for pharmaceuticals and biomaterials includes freezeREV, powderREV and bioREV.
Each technology employs a combination of microwave energy with a low pressure environment to achieve rapid, highly controlled dehydration of live or active biological materials stored in sterile vials or in bulk powder, thereby reducing the process time and cost of dehydration.
EnWave Co-CEO Tim Durance said the agreement reflects their progress towards their aim of establishing REV as a viable commercial technology in the pharmaceutical setting.